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Abstract
We measured bone mineral density (BMD) in girls with juvenile
dermatomyositis (JDM) considering multiple factors in order to deter-
mine if it could be used as a predictor of reduction in bone mass. A
cross-sectional study of lumbar spine BMD (L2-L4) was conducted on
10 girls aged 7-16 years with JDM. A group of 20 age-matched healthy
girls was used as control. Lumbar spine BMD was measured by dual-
energy X-ray absorptiometry. Weight, height and pubertal Tanner
stage were determined in all patients and controls. Duration of disease
and mean daily and cumulative steroid doses were calculated for all
patients on the basis of their medical charts. JDM activity was deter-
mined on the basis of the presence of muscle weakness, cutaneous
vasculitis and/or elevation of serum concentration of one or more
skeletal muscle enzymes. Seven patients demonstrated osteopenia or
osteoporosis. Lumbar BMD was significantly lower in the JDM
patients than the age-matched healthy control girls (0.712 vs 0.878,
respectively; Student t-test, P = 0.041). No significant correlation
between BMD and age, height, Tanner stage, disease duration, corti-
costeroid use, or disease activity was observed in JDM girls, but a
correlation was observed between BMD and weight (Pearson’s corre-
lation coefficient, r = 0.802). Patients with JDM may be at risk for a
significant reduction in BMD that might contribute to further skeletal
fragility. Our results suggest that reduced bone mass in JDM may be
related to other intrinsic mechanisms in addition to steroid treatment
and some aspects of the disease itself may contribute to this condition.
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Introduction
Osteoporosis is a disorder characterized
by loss of matrix and bone mineral content
and microarchitectural deterioration of bone
tissue (1). It used to be primarily an age-
related disorder occurring in postmenopausal
women and in the elderly, but more recently
it has been observed to be associated with
diseases such as asthma, rheumatoid arthri-
tis, dermatomyositis, and systemic lupus ery-
thematosus (SLE) (2-6). Previous studies have
assessed multiple factors as possible con-
tributors to the reduction in bone mineral
density (BMD) in patients with these dis-
eases. However, few studies on BMD have
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been conducted on the pediatric population
(7-12). Low BMD in patients with juvenile
dermatomyositis (JDM) has been associated
with a combination of factors such as dis-
ease activity, high doses of corticosteroids,
low intake of calcium, delayed pubertal stage,
low sunlight exposure, and prolonged im-
mobility. An early diagnosis of patients at
risk for bone loss is important for the attenu-
ation and management of this condition,
which may lead to a poor outcome of JDM
when not adequately treated (1).
Material and Methods
Patients
We followed the clinical course of 10
female patients with JDM aged 7 to 16 years.
All subjects fulfilled the diagnostic criteria
for JDM established by Bohan and Peter in
1975 (13). The findings were compared to
those obtained for 20 aged-matched healthy
girls selected from the community.
The Ethics Committee of Universidade
Federal de São Paulo approved the study
protocol and informed consent was obtained
from persons responsible for the participants.
Weight (kg) and height (cm) were meas-
ured in patients and controls using an anthro-
pometric balance. An experienced pediatri-
cian determined the Tanner stage. Patients
were classified into two groups: girls within
the G1-G2 Tanner range (group 1) and G3-
G5 girls (group 2). This division was due to
the fact that G3 to G5 patients present higher
bone mass (14). Duration of disease in months
was considered as the period of time from
the first clinical manifestations to the evalu-
ation by bone densitometry. Mean daily ste-
roid dose (mg prednisone kg-1 day-1) and
mean cumulative steroid dose (g) were cal-
culated from the medical records.
The medical history of JDM patients was
reviewed and disease activity was defined
on the basis of the presence of at least one of
the following four criteria: 1) muscle weak-
ness of the neck flexors and extensors, shoul-
der abductors, elbow flexors and extensors,
hip flexors, extensors, and abductors, and
knee flexors and extensors; 2) skin vasculitis
(heliotrope discoloration of the upper eye-
lids, Gottron’s papules, and abnormalities of
the periungual skin); 3) degree of impair-
ment in ambulation, and 4) elevation of one
or more serum concentrations of the skeletal
muscle enzymes (aspartate aminotransferase,
creatine kinase, aldolase, and lactic dehy-
drogenase). The presence of calcinosis
was reviewed, particularly in the lumbar
spine.
Dual-energy X-ray absorptiometry
BMD at the lumbar spine level (L2-L4)
was measured in all subjects by dual-energy
X-ray absorptiometry using a LUNAR DPX
densitometer (Lunar Radiation Corporation,
Madison, WI, USA). This site was chosen
because of its pathophysiologic importance
for vertebral compression fractures and be-
cause a high-quality age-related normative
database is available for the pediatric popu-
lation. Z scores were calculated from the
BMD data for comparison with published
normative data. The densitometer used in
our Unit has a coefficient of variation of
2.0% at the lumbar spine in children.
Lumbar spine radiography was carried
out to exclude calcinosis.
Statistical analysis
The Student t-test was used to compare
BMD of patients and controls. The chi-square
test was used to compare BMD of controls
and JDM patients with Tanner stage. In the
JDM group, Pearson’s correlation coeffi-
cient was used to detect potential associa-
tions between BMD and anthropometric
measures, time of disease, and mean daily
and cumulative steroid doses. The Student t-
test was also used to compare the BMD of
patients with Tanner stage and disease activ-
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ity. All statistical analyses were performed
using the SPSS software version 8.0. A P
value of <0.05 was considered to be statisti-
cally significant.
Results
The demographic, anthropometric and
clinical characteristics of the 10 patients and
20 controls are shown in Table 1. No patient
showed calcinosis. Seven patients had dis-
ease activity and 3 did not. Mean duration of
disease was 3.6 ± 1.6 years. Mean daily
steroid dose was 0.32 ± 0.21 mg kg-1 day-1
and mean cumulative steroid dose was 15.3
± 8.9 g. All patients with JDM were treated
with oral or intravenous corticosteroids and
at the time of evaluation all patients were
taking this medication except one. The two
groups were similar in terms of age, weight
and height, with no statistically significant
difference between them. In the JDM group,
4 patients were in stage G1-G2 and 6 were in
stage G3-G5. In the control group, 8 indi-
viduals were in stage G1-G2 and 12 were in
stage G3-G5. Pubertal development did not
show a statistically significant difference
between the two groups.
Seven patients had osteopenia or os-
teoporosis.
Patients with JDM had significantly re-
duced BMD in the lumbar spine compared to
controls (P = 0.041). In the JDM group, we
did not observe a significant correlation be-
tween BMD and age, height, disease dura-
tion, or corticosteroid use, although, a statis-
tically significant correlation was observed
between BMD and weight (r = 0.802). There
were no significant differences in BMD be-
tween JDM patients in stages G1-G2 and in
stages G3-G5 (0.645 vs 0.757 g/cm2), or
between patients with and without disease
activity (0.758 vs 0.645 g/cm2). No patients
had clinical or vertebral fractures (15).
Statistical analysis only allowed the use
of simple tests and multiple regression was
not performed.
Discussion
An important determinant of osteoporo-
sis is the peak bone mass achieved during the
second decade of life. Thus, osteopenia and
osteoporosis originate in childhood and ado-
lescence (16). Children with rheumatic dis-
eases such as juvenile SLE and JDM de-
velop a diminished bone mass both because
of the inflammatory nature of the disease
and of the use of steroids to treat the active
manifestations of the diseases (10). Because
many of these patients are diagnosed and
treated during the late prepubertal and early
pubertal periods when bone formation is
more intense, bone loss might lead to osteo-
penia and to the risk of osteoporosis during
adulthood (10). Few reports are available
about BMD in patients with JDM (10). Our
results demonstrate that children with JDM
present a reduced bone mass at the lumbar
spine level compared with healthy children.
Steroids are a mainstay drug therapy in
JDM and are a well-recognized cause of
osteoporosis in other rheumatic diseases (17-
23). Differently from other reports, our study
showed that in children with JDM there is no
significant correlation between bone mass
and steroid use, a fact possibly due to the
small number of patients included in our
study.
Table 1. Demographic, anthropometric, clinical characteristics, and bone mineral
density of patients with juvenile dermatomyositis and controls.
JDM patients Controls
Number of subjects 10 20
Age (years) 11.8 ± 3.2 12.0 ± 2.8
Weight (kg) 38.9 ± 19.4 41.2 ± 11.6
Height (cm) 137.5 ± 17.2 148.5 ± 14.4
Tanner stage G1-G2/G3-G5 4/6 8/12
Time of disease (years) 3.6 ± 1.6 -
Daily steroid doses (mg kg-1 day-1) 0.32 ± 0.21 -
Cumulative steroid doses (g) 15.3 ± 8.9 -
Spine bone mineral density (g/cm2) 0.712 ± 0.239* 0.878 ± 0.179
Data are reported as means ± SD. JDM = juvenile dermatomyositis.
*P < 0.05 compared to controls (Student t-test).
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There are many disease-related variables,
like reduced serum osteocalcin levels or el-
evated serum cytokines, that could play a
role in determining the BMD of patients with
JDM (26-28). Secondary mechanisms re-
sulting in increased susceptibility to bone
loss include female sex, immobility due to
muscle weakness and constitutional symp-
toms like anorexia, the deliberate avoidance
of sunlight exposure, gastrointestinal vascu-
litis impairing calcium and vitamin D ab-
sorption, and ovarian failure associated with
the disease itself or secondary to cytotoxic
therapy (29,30). None of these factors were
evaluated in our study and perhaps could
explain the reduced bone mass in JDM chil-
dren. Disease activity and steroid treatment
did not correlate with BMD in these patients.
The present results suggest that the reduced
bone mass observed in these children repre-
sents a multifactorial process and some as-
pects of JDM itself may contribute to this
condition.
It is important to emphasize that the small
sample size of the present study limited our
ability to generalize our findings.
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Perez et al. (10) showed a significant
bone loss associated with decreased calcium
absorption in 12 JDM patients receiving ste-
roid therapy. Falcini et al. (1) observed a
reduction in both lumbar spine BMD and
calcaneal ultrasound measurements in 53
patients with juvenile rheumatoid arthritis
(N = 29), juvenile SLE (N = 13) and JDM (N
= 11) compared with a control group. All
JDM patients were taking corticosteroids.
Our results show that weight was statisti-
cally correlated with bone mass in JDM
patients. This finding agrees with others
showing that weight is the best predictor of
bone mass in healthy children (24,25).
The most important increase in lumbar
spine BMD was found in pubertal stage 4 for
both sexes (14). It is during this stage of
puberty that the deceleration of the growth
spur occurs and adult levels of sex steroids
can be attained (14). In our study, we did not
find a significant correlation between bone
loss and pubertal stage. However, JDM pa-
tients who were in stages G1-G2 presented
lower BMD than patients in stages G3-G5.
Our results indicate some increment in bone
mass as a function of pubertal development
even in patients with an important reduction
in bone density.
All children with osteopenia or osteoporo-
sis were being treated with calcium and vita-
min D.
References
1. Falcini F, Bindi G, Ermini M, Galluzzi F, Poggi G, Rossi S, Masi L,
Cimaz R & Brandi ML (2000). Comparison of quantitative calcaneal
ultrasound and dual energy X-ray absorptiometry in the evaluation
of osteoporotic risk in children with chronic rheumatic diseases.
Calcified Tissue International, 67: 19-23.
2. Kalla AA, Fataar AB, Jessop SJ & Bewerunge L (1993). Loss of
trabecular bone mineral density in systemic lupus erythematosus.
Arthritis and Rheumatism, 36: 1726-1734.
3. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F & Roig-Escofet D
(1995). Loss of bone mineral density in premenopausal women with
systemic lupus erythematosus. Annals of the Rheumatic Diseases,
54: 274-276.
4. Sinigaglia L, Varenna M, Binelli L, Zucchi F, Ghiringhelli D & Fantini F
(2000). Bone mass in systemic lupus erythematosus. Clinical and
Experimental Rheumatology, 18 (Suppl 21): S27-S34.
5. Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S &
Champion GD (1986). Osteoporosis in rheumatoid arthritis: safety
of low dose corticosteroids. Annals of the Rheumatic Diseases, 45:
950-953.
6. Sambrook PN, Cohen ML, Eisman JÁ, Pocock NA, Champion GD &
Yeates MG (1989). Effects of low dose corticosteroids on bone
mass in rheumatoid arthritis: a longitudinal study. Annals of the
Rheumatic Diseases, 48: 535-538.
7. Pepmueller PH, Cassidy JT, Allen SH & Hillman LS (1996). Bone
mineralization and bone mineral metabolism in children with juve-
nile rheumatoid arthritis. Arthritis and Rheumatism, 39: 746-757.
8. Pereira RMR, Corrente JE, Chahade WH & Yoshinari NH (1998).
Evaluation by dual X-ray absorptiometry (DXA) of bone mineral
density in children with juvenile chronic arthritis. Clinical and Exper-
imental Rheumatology, 16: 495-501.
313
Braz J Med Biol Res 38(2) 2005
Bone mineral density of girls with juvenile dermatomyositis
9. Brik R, Keidar Z, Schapira D & Israel O (1998). Bone mineral density
and turnover in children with systemic juvenile chronic arthritis.
Journal of Rheumatology, 25: 990-992.
10. Perez MD, Abrams AS, Koenning G, Stuff JE, O’Brien KO & Ellis KJ
(1994). Mineral metabolism in children with dermatomyositis. Jour-
nal of Rheumatology, 21: 2364-2369.
11. Trapani S, Civinini R, Ermini M, Paci E & Falcini F (1998). Osteoporo-
sis in juvenile systemic lupus erythematosus: a longitudinal study
on the effect of steroids on bone mineral density. Rheumatology
International, 18: 45-49.
12. Stewart WA, Acott PD, Salisbury SR & Lang BA (2003). Bone
mineral density in juvenile dermatomyositis. Arthritis and Rheuma-
tism, 48: 2294-2298.
13. Bohan A & Peter J (1975). Polymyositis and dermatomyositis. New
England Journal of Medicine, 292: 344-347.
14. De Schepper J, Derde MP, Van Den Broeck M, Piepsz A &
Jonckheer MH (1991). Normative data for lumbar spine bone min-
eral content in children: Influence of age, height, weight and puber-
tal stage. Journal of Nuclear Medicine, 32: 216-220.
15. Genant HK, Wu CY, van Kuijk C & Nevitt MC (1993). Vertebral
fracture assessment using a semiquantitative technique. Journal of
Bone and Mineral Research, 8: 1137-1148.
16. Cassidy JT (1999). Osteopenia and osteoporosis in children. Clinical
and Experimental Rheumatology, 17: 245-250.
17. Warady BD, Lindsley CB, Robinson FG & Lukert BP (1994). Effects
of nutritional supplementation on bone mineral status of children
with rheumatic diseases receiving corticosteroid therapy. Journal
of Rheumatology, 21: 530-535.
18. Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL,
Hahn TJ & Hahn BH (1984). Effects of oral 1,25-dihydroxyvitamin D
and calcium on glucocorticoid-induced osteopenia in patients with
rheumatic diseases. Arthritis and Rheumatism, 27: 1336-1343.
19. Dykman TR, Gluck OS, Murphy WA, Hahn TJ & Hahn BH (1985).
Evaluation of factors associated with glucocorticoids-induced os-
teopenia in patients with rheumatic diseases. Arthritis and Rheuma-
tism, 28: 361-368.
20. Hajiroussou VJ & Webley M (1984). Prolonged low-dose cortico-
steroid therapy and osteoporosis in rheumatoid arthritis. Annals of
the Rheumatic Diseases, 43: 24-27.
21. Dhillon BV, Davies MC, Hall ML, Round JM, Ell PJ, Jacobs HS,
Snaith ML & Isenberg DA (1990). Assessment of the effect of oral
corticosteroids on bone mineral density in systemic lupus erythe-
matosus: a preliminary study with dual energy X-ray absorptio-
metry. Annals of the Rheumatic Diseases, 49: 624-626.
22. Pons F, Peris P, Guanabens N, Font J, Huguet M, Espinosa G,
Ingelmo M, Munoz-Gomez J & Setoain J (1995). The effect of
systemic lupus erythematosus and long-term steroid therapy on
bone mass in premenopausal women. British Journal of Rheuma-
tology, 34: 742-746.
23. Reid IR (1989). Pathogenesis and treatment of steroid osteoporosis.
Clinical Endocrinology, 30: 83-103.
24. Bonjour JP, Theintz G, Buchs B, Slosman D & Rizzoli R (1991).
Critical years and stages of puberty for spinal and femoral bone
mass accumulation during adolescence. Journal of Clinical Endocri-
nology and Metabolism, 73: 555-563.
25. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC
& Bonjour JP (1992). Longitudinal monitoring of bone mass accu-
mulation in healthy adolescents: evidence for a marked reduction
after 16 years of age at the levels of lumbar spine and femoral neck
in female subjects. Journal of Clinical Endocrinology and Metabo-
lism, 75: 1060-1065.
26. Reed A, Haugen M, Patchman LM & Langman CB (1990). Abnor-
malities in serum osteocalcin values in children with chronic rheu-
matic diseases. Journal of Pediatrics, 116: 574-580.
27. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L &
Lundberg I (2000). Cytokine production, serum levels and disease
activity in systemic lupus erythematosus. Clinical and Experimental
Rheumatology, 18: 565-570.
28. Tanaka Y, Watanabe K, Suzuki M, Saito K, Oda S, Suzuki H, Eto S &
Yamashita U (1989). Spontaneous production of bone-resorbing
lymphokines by B cells in patients with systemic lupus erythemato-
sus. Journal of Clinical Immunology, 9: 415-420.
29. Babini SM, Arturi A, Marcos JC, Babini JC, Iniguez AM & Morteo
OG (1988). Laxity and rupture of the patellar tendon in systemic
lupus erythematosus. Association with secondary hyperparathy-
roidism. Journal of Rheumatology, 15: 1162-1165.
30. Wallace DJ (1993). The endocrine system and urogenital tract. In:
Wallace DJ & Hahn BH (Editors), Dubois’ Lupus Erythematosus.
Lea and Febiger, Philadelphia, PA, USA, 407.
